Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in JapanReport as inadecuate

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan - Download this document for free, or read online. Document in PDF available to download.

Clinical Rheumatology

, Volume 31, Issue 12, pp 1713–1721

First Online: 02 October 2012Received: 12 April 2012Revised: 01 August 2012Accepted: 28 August 2012


The objective of this study was to evaluate the efficacy, pharmacokinetics, and safety of adalimumab in patients with polyarticular juvenile idiopathic arthritis JIA in Japan. Patients aged 4 to 17 years were enrolled in a single-arm, open-label, multicentre study of adalimumab. Patients weighing <30 kg received 20 mg every other week eow, and those ≥30 kg received 40 mg eow. Concomitant methotrexate MTX was allowed ≤10 mg-m per week. The primary efficacy outcome was the percent of patients with American College of Rheumatology Pediatric 30 response ACR Pedi 30 at week 16. JIA core variables, serum adalimumab concentrations, and anti-adalimumab antibodies AAAs were analysed. Patients were monitored for adverse events AEs. Twenty-five patients 20 with concomitant MTX at baseline and 5 without were enrolled: 24 patients completed 16 weeks of therapy and 22 patients completed 60 weeks. At week 16, 90 % of patients with MTX and 100 % without MTX achieved ACR Pedi 30; response rates were maintained through week 60 in 94 and 80 % of patients, respectively. Each JIA core variable improved over time. Six patients became AAA positive two each at weeks 8, 16, and 60, some of which were transient. All six AAA-positive patients achieved ACR Pedi 30 at week 16, and four maintained that response at week 60. Six patients all with MTX experienced nine serious AEs JIA, pyrexia, arthralgia, pneumonia, hepatitis B infection, pharyngitis, dehydration, pharyngeal pain, and pneumonia. In pediatric patients with polyarticular JIA in Japan, adalimumab was safe and effective for reducing disease activity for up to 60 weeks.

KeywordsAdalimumab Juvenile idiopathic arthritis Methotrexate Pharmacokinetics  Download fulltext PDF

Author: Tomoyuki Imagawa - Syuji Takei - Hiroaki Umebayashi - Kenichi Yamaguchi - Yasuhiko Itoh - Toshinao Kawai - Naomi Iwata - Ta

Source: https://link.springer.com/

Related documents